SELLAS Life Sciences Group, Inc. (SLS) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc.
Is SELLAS Life Sciences Group, Inc. stock overvalued or undervalued in 2026?
As of October 28, 2026, SELLAS Life Sciences Group, Inc. (SLS) trades at $10.38 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: there is not enough data to compare it with.
Kaplio overview: SELLAS Life Sciences Group, Inc.
Market cap $2B · 52 weeks $1 – $15 (21 % below the high) · P/E no earnings · Dividend none · Next earnings November 18, 2026 · expected EPS $-0.05 · Closing price, Oct 28 · accounts published Aug 11.
- Balance sheet: Safe zone (solid).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: there is not enough data to compare it with.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 15.7×, fails.
- Cash Runway 30 meses, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $0.26, info.
Against its peers (reference peers) — SELLAS Life Sciences Group, Inc.: P/E —; EV/EBITDA —; ROIC -25.4 %; $2.1B. Nurix Therapeutics, Inc. (P/E 11.8×; EV/EBITDA 6.6×; ROIC 25.9 %; $3.0B), Incyte Corporation (P/E 14.9×; EV/EBITDA 9.2×; ROIC 24.6 %; $23.7B), Lakefront Biotherapeutics N.V. (P/E 3.9×; EV/EBITDA 5.2×; ROIC 11.6 %; $2.1B).
Profitability
| Return on Equity | -35.91% |
| Return on Invested Capital | -25.45% |
| Return on Assets | -22.33% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 18.83 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 27.94 |
Price Performance
| 1 month | +5.73% |
| 3 months | +21.58% |
| Year-to-date | +222.81% |
| 1 year | +485.10% |
| 3 years | +949.14% |
| 5 years | +40.05% |
| 10 years | -99.82% |
Related companies: INCY · IDYA · IMNM · NRIX
Explore sector: Healthcare · Biotechnology
More sections of SLS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks